Insulin-Producing Stem Cell Discovery Points to New Diabetes Treatment Approach

Scientists at the Walter and Eliza Hall Institute recently discovered that the pancreas contains stem cells that can be turned into insulin-producing cells.  This new research provides hope that patients who currently suffer from type 1 diabetes may one day be able to regrow their own insulin producing pancreatic beta cells.   Researchers are thus turning to stem cells to address a defining aspect of Type 1 Diabetes – the destruction of the pancreas while also seeking ways to modulate the patient’s immune system to prevent it from destroying the new, regenerated pancreatic tissue.

Continue reading

Alzheimer’s Awareness Month








Alzheimer’s is a neurodegenerative disorder currently affecting 5 million people in the U.S. and 35 million across the globe.  As the global population ages, the number of people affected is growing rapidly.  November is National Alzheimer’s Disease Awareness Month with the goal of raising awareness of a disease that touches almost everyone.

Continue reading

Stem Cell and Regenerative Medicine Conference at Cambridge University

shaking hands







UniverCELLmarket is holding its second ‘Enabling Technologies for Stem Cell and Regenerative Medicine Research’  conference’ at Cambridge University on November 28th, 2012. The conference brings together researchers and industry experts to share ideas, research, services and products to advance regenerative medicine.

Continue reading

FDA Approves Clinical Trial Using Mesenchymal Stem Cells Idiopathic Pulmonary Fibrosis

mesenchymal stem cell









Researchers at University of Miami Health System receive FDA approval for the first U.S. clinical trial using mesenchymal stem cells to treat idiopathic pulmonary fibrosis. Mesenchymal stem cells are multipotent adult stem cells that can be isolated from bone marrow, teeth, and fat.  Mesenchymal stem cells have demonstrated the ability to differentiate into bone, cartilage, cardiomyocites, muscle, neuronal cells, insulin producing pancreatic beta cells and more.

Continue reading

Wake Forest Study Provides Insights into Organ Regeneration for Humans

rat bladder






Researchers at Wake Forest Baptist Medical Center’s Institute for Regenerative Medicine reported their findings in an animal study in which rats were able to re-grow their bladders in as little as 8 weeks. The focus of the study was to better understand the regenerative process at work in the re-growth of the bladder.

Continue reading

Reprogrammed Cells Could Reverse Vascular Disease

What if medicine could one day repair injured organs and reverse damage that we now think of as irreversible?

At Weill Cornell Medical College, researchers have recently gotten one step closer to doing just that.

The research team discovered a way to reprogram diagnostic prenatal amniocentesis cells (a type of stem cell)  into abundant and stable endothelial cells.  It is these types of cells that are capable of regenerating damaged blood vessels and organs.

Continue reading

Governor Perry Pushes Texas to Become Major Stem Cell Research Center

“Adult stem cells and regenerative medicine hold the promise of miracles,” says Governor Rick Perry at the recently concluded Houston Stem Cell Summit. Governor Perry, who underwent a successful autologous [his own] stem cell treatment to relieve chronic back pain, was a keynote speaker at the Summit during which he pushed for Texas to become a key center for adult stem-cell research.

Continue reading

Stem Cell Treatment for Dry Age-Related Macular Degeneration Entering Clinical Trial Phase







A Phase I/II clinical trial to treat dry age-related macular degeneration (Dry-AMD) is being conducted by StemCells, Inc.  Dry-AMD is the most common type of macular degeneration and affects 90% of patients with the condition. It is a chronic eye disease that causes vision loss in the center of the field of vision and is the major cause of blindness and visual impairment in adults older than 50.

Continue reading

Autologous Stem Cells Utilized in Phase II Clinical Trial to Treat Multiple Myeloma








Researchers at the Virginia Commonwealth University’s Masey Cancer Center have developed an innovative approach to the treatment of multiple myeloma.  The Phase II Clinical trial involves a process to ‘mark’ cancerous cells and also boost the body’s immune system – by removing the patient’s stem cells, manipulating them in-vitro [outside the body] and then reintroducing the stem cells back into the patient – to destroy the cancerous cells.  Researchers believe the reprogrammed stem cells will also prevent any future recurrence of multiple myeloma.

Continue reading